RxDoctor Payments Data

Chandrakala Rudraraju, MD

Family Medicine · Bakersfield, CANPI 1699977314

Payments from drug & device makers

$958in general payments, 2019–2025

Across 57 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$279
  • AstraZeneca$137
  • Boehringer Ingelheim$125
  • GSK$121
  • Lilly USA, LLC$110
  • Johnson & Johnson$56
  • plus $130 from 6 others

What the payments were for

  • Food & beverage$958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$958 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$7,860
Medicare patients
23
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$92,629
OzempicSemaglutide77$92,365
TradjentaLinagliptin80$69,930
JanuviaSitagliptin Phosphate76$58,652
EliquisApixaban46$50,939
MounjaroTirzepatide27$40,495
TrulicityDulaglutide31$29,196
FarxigaDapagliflozin Propanediol22$26,452
XareltoRivaroxaban32$25,599
MyrbetriqMirabegron28$21,149
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,632
Tresiba Flextouch U-100Insulin Degludec25$14,345
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$11,977
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$10,809
Combivent RespimatIpratropium/Albuterol Sulfate17$7,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$125$170,517168 claims
Novo NordiskOzempic, Levemir$279$94,20188 claims
Lilly USA, LLCMounjaro, Trulicity$110$69,69158 claims
MerckJanuvia$45$58,65276 claims
PfizerEliquis$16$50,93946 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$121$35,92768 claims
AstraZenecaFarxiga$137$26,45222 claims
Johnson & JohnsonXarelto$56$25,59932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →